Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Anixa Biosciences, Inc.NASDAQ: ANIX

Cash & Equivalents · Q2 FY2026 · quarter ended Apr 2026

Cash & equivalents falls 22.7% from a year ago

Cash & equivalents stood at $1.48M at the end of Q2 FY2026, down 22.7% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -53.5% a year.

Context

  • Cash & equivalents amounted to 9.9% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -22.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterApr 2026
$1.48M-4.5% QoQ
Last fiscal yearOct 2025
$1.24M-2.1% YoY
Year agoApr 2025
$1.91M-22.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.7%——
1 year-2.1%——
3-year CAGR-53.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
1.24M USD
Year-over-year change
-2.1%
4-year CAGR
-54.5%

Cash & Equivalents vs competitors

How ANIX compares with its peers on the latest reported figures

  • ANIX's Apr 2026 cash & equivalents of $1.48M is the lowest of the 10 companies compared; the peer median is $35M.
  • Its year-over-year change of -22.7% is the 8th highest of 10, against a peer median of +14.8%.
  • Cash & equivalents amounts to 9.9% of total assets for ANIX, versus a peer median of 38.8%.
ANIX Competitors Peer median
Cash & Equivalents for ANIX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRDOpus Genetics, Inc.Mar 2026$59.96M +43.5%+1.9%89.8%
SPROSpero Therapeutics, Inc.Mar 2026$56.13M +14.8%-28.3%95.1%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$51.8M +71.7%-25.4%38.8%
SEERSeer, Inc.Mar 2026$47.32M -9.8%-3.9%17.4%
AGENAgenus Inc.Mar 2026$35M +89.3%-74.4%18.8%
INOInovio Pharmaceuticals, Inc.Mar 2026$26.27M -34.2%-1.5%52.8%
ACTUActuate Therapeutics IncMar 2026$8.13M +109.1%-13.7%91.3%
HURATuHURA Biosciences, Inc.Mar 2026$6.3M +1.3%-36.7%21.2%
ENTXEntera Bio Ltd.Mar 2026$4.14M -67.1%-16.7%31.5%
ANIXAnixa Biosciences, Inc.Apr 2026$1.48M -22.7%-53.5%9.9%
Peer median (excluding ANIX) $35M+14.8%-16.7%38.8%

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Cash & Equivalents29.13M12.36M915K1.27M1.24M
Short-term Investments6.6M17.33M22.93M18.65M13.93M
Net Receivables046K270K173K0
Inventory0(46K)000
Other Current Assets(444)46K1.24M1.27M713K
Total Current Assets36M30.2M25.36M21.36M15.89M
Property, Plant & Equipment (Net)253.96K212K166K229K193K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets253.96K212K166K229K193K
Total Assets36.26M30.41M25.52M21.59M16.08M
Account Payables136K265K206K525K165K
Short-term Debt000041K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0000922K
Total Current Liabilities1.27M2.04M2.03M2.5M1.97M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities820000
Total Non-current Liabilities220.08K175K123K203K163K
Total Liabilities1.49M2.21M2.15M2.7M2.13M
Common Stock300.51K309K311K322K330K
Retained Earnings(204.79M)(218.39M)(228.2M)(240.75M)(251.68M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest(670.51K)(847K)(966K)(1.11M)(1.21M)
Total Equity34.77M28.2M23.37M18.89M13.95M
Total Debt259K221K175K232K204K
Net Debt(28.83M)(12.14M)(740K)(1.04M)(1.04M)

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.